35 million US dollars introduction!

According to information from the Chinese drug clinical trial registration and information disclosure platform, Qilu Pharmaceutical has initiated a phase 3 clinical trial on antibody-conjugated drug (ADC) Vicinium (VB4-845) to evaluate the treatment of non-muscular infiltration by VB4-845 injection The effectiveness and safety of patients with sexual bladder cancer.

According to the information published on the China Drug Clinical Trial Registration and Information Disclosure Platform, this is a non-randomized, single-arm, open multi-center Phase 3 clinical study launched in China to evaluate the use of VB4-845 for BCG bladder perfusion therapy The efficacy and safety of patients who fail after non-muscular invasive bladder cancer, including carcinoma in situ (CIS) with or without papillary carcinoma, and high-grade Ta stage or any grade T1 stage papillary carcinoma.

Public information shows that this clinical trial will be carried out in 29 research institutions in China, with the goal of enrolling 53 patients.

In fact, the therapeutic potential of VB4-845 has been verified in clinical trials.

Public information shows that about 80% of patients with bladder cancer are NMIBC, and NMIBC mainly affects men.

We look forward to the smooth progress of clinical research of VB4-845, a new generation of antibody-conjugated drug in China, and its market launch as soon as possible, bringing new treatment options to patients.